Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research

Oxford University Press (OUP) - Tập 22 Số 10 - Trang 1479-1491 - 2007
Sundeep Khosla1, David B. Burr1, Jane A. Cauley1, David W. Dempster1, Peter R. Ebeling1, Dieter Felsenberg1, Robert F. Gagel1, Vincente Gilsanz1, Theresa A. Guise1, Sreenivas Koka1, Laurie K. McCauley1, Joan McGowan1, Marc D. McKee1, Suresh Mohla1, David G. Pendrys1, Lawrence G. Raisz1, Salvatore L. Ruggiero1, David Shafer1, Lillian Shum1, Stuart L. Silverman1, Catherine Van Poznak1, Nelson B. Watts1, Sook-Bin Woo1, Elizabeth Shane1
1ASBMR Task Force on Bisphosphonate-Associated ONJ

Tóm tắt

Abstract

ONJ has been increasingly suspected to be a potential complication of bisphosphonate therapy in recent years. Thus, the ASBMR leadership appointed a multidisciplinary task force to address key questions related to case definition, epidemiology, risk factors, diagnostic imaging, clinical management, and future areas for research related to the disorder. This report summarizes the findings and recommendations of the task force.

Introduction: The increasing recognition that use of bisphosphonates may be associated with osteonecrosis of the jaw (ONJ) led the leadership of the American Society for Bone and Mineral Research (ASBMR) to appoint a task force to address a number of key questions related to this disorder.

Materials and Methods: A multidisciplinary expert group reviewed all pertinent published data on bisphosphonate-associated ONJ. Food and Drug Administration drug adverse event reports were also reviewed.

Results and Conclusions: A case definition was developed so that subsequent studies could report on the same condition. The task force defined ONJ as the presence of exposed bone in the maxillofacial region that did not heal within 8 wk after identification by a health care provider. Based on review of both published and unpublished data, the risk of ONJ associated with oral bisphosphonate therapy for osteoporosis seems to be low, estimated between 1 in 10,000 and <1 in 100,000 patient-treatment years. However, the task force recognized that information on incidence of ONJ is rapidly evolving and that the true incidence may be higher. The risk of ONJ in patients with cancer treated with high doses of intravenous bisphosphonates is clearly higher, in the range of 1–10 per 100 patients (depending on duration of therapy). In the future, improved diagnostic imaging modalities, such as optical coherence tomography or MRI combined with contrast agents and the manipulation of image planes, may identify patients at preclinical or early stages of the disease. Management is largely supportive. A research agenda aimed at filling the considerable gaps in knowledge regarding this disorder was also outlined.

Từ khóa


Tài liệu tham khảo

Shane, 2006, Osteonecrosis of the jaw: More research needed, J Bone Miner Res, 10, 1503, 10.1359/jbmr.060712

Sambrook, 2006, Bisphosphonates and osteonecrosis of the jaw, Aust Family Phys, 35, 801

Felsenberg, 2006, Bisphosphonattherapie assoziierte, Kiefernekrosen Deutsches Arzteblatt, 46, A3078

Mavrokokki, 2007, Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia, J Oral Maxillofac Surg, 65, 415, 10.1016/j.joms.2006.10.061

Body, 2003, Effectiveness and cost of bisphosphonate therapy in tumor bone disease, Cancer, 97, 859, 10.1002/cncr.11139

Ramaswamy, 2003, Bisphosphonates in the prevention and treatment of bone metastases, Oncology (Williston Park), 17, 1261

Hillner, 2003, American Society of Clinical Oncology update on the role of bisphosphonates and bone health issues in women with breast cancer, J Clin Oncol, 21, 4042, 10.1200/JCO.2003.08.017

Berenson, 2002, American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma, J Clin Oncol, 20, 3719, 10.1200/JCO.2002.06.037

Coleman, 2004, Bisphosphonates: Clinical experience, The Oncologist, 9, 14, 10.1634/theoncologist.9-90004-14

Ruggiero, 2004, Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases, J Oral Maxillofac Surg, 62, 527, 10.1016/j.joms.2004.02.004

Woo, 2006, Systematic review: Bisphosphonates and osteonecrosis of the jaws, Ann Intern Med, 144, 753, 10.7326/0003-4819-144-10-200605160-00009

Durie, 2005, Osteonecrosis of the jaw and bisphosphonates, N Engl J Med, 353, 99, 10.1056/NEJM200507073530120

Hoff, 2006, Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy, Clin Oncol, 24, 8528

Van Poznak, 2004, Osteonecrosis of the maxilla and mandible in patients with metastatic breast cancer, J Bone Miner Res, 19, S227

Maerevoet, 2005, Osteonecrosis of the jaw and bisphosphonates, N Engl J Med, 353, 99, 10.1056/NEJM200507073530120

Zavras, 2006, Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: Is it osteonecrosis?, J Oral Maxillorfac Surg, 64, 917, 10.1016/j.joms.2006.02.011

Bamias, 2005, Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk Factors, J Clin Oncol, 23, 8580, 10.1200/JCO.2005.02.8670

American Dental Association Division of Communications, 2002, For the patient: Oral care for cancer patients, J Am Dent Assoc, 133, 1014, 10.14219/jada.archive.2002.0308

Migliorati, 2005, Managing the care of patients with bisphosphonate-associated osteonecrosis. An American Academy of Oral Medicine position paper, J Am Dent Assoc, 136, 1658, 10.14219/jada.archive.2005.0108

Ruggiero, 2006, Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer, J Oncol Pract, 2, 7, 10.1200/jop.2006.2.1.7

Marx, 2005, Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment, J Oral Maxillofac Surg, 63, 1567, 10.1016/j.joms.2005.07.010

Estilo, 2004

Chiandussi, 2006, Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws, Dentomaxillofac Radiol, 35, 236, 10.1259/dmfr/27458726

Store, 2000, Mandibular osteoradionecrosis: Clincal behavious and diagnostic aspects, Clin Otolaryngol, 25, 378, 10.1046/j.1365-2273.2000.00367.x

Store, 1999, Mandibular osteoradionecrosis: A comparison of computed tomography with panoramic radiography, Dentomaxillofac Radiol, 28, 295, 10.1038/sj.dmfr.4600461

Schulze, 2006, Diagnostic criteria for the detection of mandibular osteomyelitis using cone-beam computed tomography, Dentomaxillofac Radiol, 35, 232, 10.1259/dmfr/71331738

Guerrero, 2006, State-of-the-art on cone beam CT imaging for preoperative planning of implant placement, Clin Oral Investig, 10, 1, 10.1007/s00784-005-0031-2

Gabriel, 1994, MR imaging of hip disorders, Radiographics, 14, 763, 10.1148/radiographics.14.4.7938767

Larheim, 1999, Osteonecrosis of the temporomandibular joint: Correlation of magnetic resonance imaging and histology, J Oral Maxillofac Surg, 57, 888, 10.1016/S0278-2391(99)90001-0

Colston, 2000, Imaging of the oral cavity using optical coherence tomography, Monogr Oral Sci, 17, 32, 10.1159/000061643

Hall, 2004, A review of potential new diagnostic modalities for caries lesions, J Dent Res, 83, C89, 10.1177/154405910408301s18

Baumgartner, 2000, Polarization-sensitive optical coherence tomography of dental structures, Caries Res, 34, 59, 10.1159/000016571

American Dental Association, 2006, Dental management of patients receiving oral bisphosphonate therapy: Expert panel recommendations, J Am Dent Assoc., 137, 1144, 10.14219/jada.archive.2006.0355

American Association of Endodontists (AAE) Special Committee on Bisphosphonates, 2006

Ruggiero, 2004, Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases, J Oral Maxillofac Surg, 62, 527, 10.1016/j.joms.2004.02.004

Ruggiero, 2006, Bisphosphonate-related osteonecrosis of the jaw: Background and guidelines for diagnosis, staging and management, Oral Surg Oral Med Oral Path Oral Radiol Endod, 102, 433, 10.1016/j.tripleo.2006.06.004

Melo, 2006, Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: Strategies for prevention and early recognition, J Am Dent Assoc, 136, 1675, 10.14219/jada.archive.2005.0110

Cheng, 2005, The dental implications of bisphosphonates and bone disease, Aust Dent J, 50, S4, 10.1111/j.1834-7819.2005.tb00384.x

Marunick, 2005, Adverse oral sequelae to bisphosphonate administration, J Mich Dent Assoc, 87, 44

Purcell, 2005, Bisphosphonates and osteonecrosis of the jaw, Med J Aust, 182, 417, 10.5694/j.1326-5377.2005.tb06762.x

Farrugia, 2006, Osteonecrosis of the Mandible or Maxilla Associated with the use of New Generation Bisphosphonates, Laryngoscope, 116, 115, 10.1097/01.mlg.0000187398.51857.3c

Chang, 2004

Starck, 1995, Failure of osseointegrated dental implants after diphosphonate therapy for osteoporosis: A case report, Int J Oral Maxillofac Implants, 10, 74

Hoefert, 2005, Necrosis of the jaws under bisphosphonate therapy, Orthopade, 35, 204, 10.1007/s00132-005-0901-y

Najm, 2005, Osteonecrose des maxillaries chez des patients traits par bisphosphonates, J Presse Med, 34, 1073, 10.1016/S0755-4982(05)84119-3

Carter, 2005, Bisphosphonates and avascular necrosis of the jaw: A possible association, Med J Aust, 182, 413, 10.5694/j.1326-5377.2005.tb06761.x

Pozzi, 2005, Analysis of frequency and risk factors for developing bisphosphonate associated osteonecrosis of the jaw, Blood, 106, A5057, 10.1182/blood.V106.11.5057.5057